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Nerve growth factor engages two structurally
distinct transmembrane receptors, TrkA and
p75, which have been proposed to create a
‘‘high-affinity’’ NGF binding site through forma-
tion of a ternary TrkA/NGF/p75 complex. To
define a structural basis for the high-affinity
site, we have determined the three-dimensional
structure of a complete extracellular domain
of TrkA complexed with NGF. The complex re-
veals a crab-shaped homodimeric TrkA struc-
ture, but a mechanism for p75 coordination is
not obvious. We investigated the heterodimeri-
zation of membrane-bound TrkA and p75, on
intact mammalian cells, using a b-gal protein-
protein interaction system. We find that NGF
dimerizes TrkA and that p75 exists on the cell
surface as a preformed oligomer that is not
dissociated by NGF. We find no evidence for
a direct TrkA/p75 interaction. We propose that
TrkA and p75 likely communicate through con-
vergence of downstream signaling pathways
and/or shared adaptor molecules, rather than
through direct extracellular interactions.
INTRODUCTION
NerveGrowth Factor is the foundingmember of the neuro-
trophins, which are a family of secreted proteins essential
for the proper development, patterning, and maintenance
of the mammalian nervous system (Bothwell, 1995; Chao,
2003; Cohen, 1959; Dechant and Barde, 2002; Roux and
Barker, 2002). NGF binds to two type-I cell-surface pro-
teins with high affinity, the p75 receptor (Johnson et al.,
1986), a member of the death-promoting Tumor Necrosis
Factor family of receptors; and TrkA, a receptor tyrosine
kinase (Kaplan et al., 1991; Klein et al., 1991). All neurotro-
phins (NT-3, NT-4/5, BDNF) bind to p75, while each NT isspecific for a different Trk receptor subtype (A-, B-, and C)
(Huang and Reichardt, 2003; Kalb, 2005). The ability of
NGF, and its NT family relatives, to bind two receptors
of such disparate structure, which are expressed on the
same cell surfaces, has spurred a long-standing debate
regarding the molecular mechanism of signaling via this
complex receptor system (Bothwell, 1995; Chao, 2003;
Huang and Reichardt, 2003; Lad et al., 2003; Roux and
Barker, 2002; Teng and Hempstead, 2004).
Both TrkA and p75 receptors have nanomolar affinities
for NGF, and evidence from a variety of systems has sug-
gested they may cooperate in transducing NGF signals
(Bibel et al., 1999; Huang and Reichardt, 2003; Yano
and Chao, 2000). The expression patterns of these two
receptors overlap extensively (Karchewski et al., 1999;
Rifkin et al., 2000), and in some instances, such as the
neurons of the dorsal root ganglion, TrkA is exclusively
expressed with p75 (Wright and Snider, 1995). In vitro,
neurons coexpressing p75 and TrkA respond to lower
concentrations of NGF than cells expressing TrkA alone
(Barker and Shooter, 1994; Hantzopoulos et al., 1994;
Verdi et al., 1994). p75 knockout mice require higher
concentrations of NGF than normal for survival (Lee
et al., 1992; von Schack et al., 2001). When the two recep-
tors are coexpressed, the rate of association of NGF with
TrkA increases (Mahadeo et al., 1994), and the presence
of p75 has been reported to modulate the neurotrophin
selectivity of Trk receptors. Using Scatchard analysis,
it has been shown that coexpression of p75 and TrkA
appears to result in the formation of a ‘‘high-affinity’’ bind-
ing site that has a 30- to 100-fold higher affinity for NGF
than either receptor alone (Hempstead et al., 1991). On
the other hand, the high-affinity binding sites appear
to constitute only 10%–15% of the total NGF binding sites
on cells transfected with both receptors, and several
reports find no evidence for p75 influencing TrkA binding
to NGF (Bothwell, 1995; Jing et al., 1992; Klein et al.,
1991).
While many biochemical and cellular studies indicate
the involvement of both receptors in NGF signaling, the
mechanism for how these two receptors coordinate to
produce a seemingly synergistic effect has been difficultNeuron 53, 25–38, January 4, 2007 ª2007 Elsevier Inc. 25
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high-affinity binding is achieved through the formation of
a p75/TrkA heterocomplex, perhaps involving allosteric
communication between the receptors (Hempstead
et al., 1991; Huang and Reichardt, 2003; Lad et al.,
2003; Mischel et al., 2001; Yano and Chao, 2000). Al-
though some groups can crosslink and/or coimmuno-
precipitate a small fraction of these complexes from cells
(Bibel et al., 1999; Huber andChao, 1995; Lad et al., 2003),
others have failed to observe the interaction (Jing et al.,
1992). Similarly, definition of the protein domains neces-
sary for the formation of the high-affinity binding sites on
p75 or TrkA have led to conflicting results (Battleman
et al., 1993; Bilderback et al., 2001; Esposito et al., 2001;
Hempstead et al., 1990) (Mischel et al., 2001), thus failing
to provide a molecular basis for the formation of the
high-affinity sites (Bothwell, 1995; Huang and Reichardt,
2003). An alternative hypothesis is that p75 indirectly
influences Trk by binding NGF at the cell surface and rais-
ing the local effective NGF concentration for TrkA (Barker
and Shooter, 1994).
Current structural inferences can be derived from a ho-
modimeric (2:2) structure of NGF complexed with a single
C-terminal immunoglobulin ligand-binding domain (D5 or
Ig-C2) of TrkA (Wiesmann et al., 1999). However, some
debate persists as to whether this single domain is a faith-
ful representation of the full-length receptor extracellular
domain (ECD) interaction (Arevalo et al., 2000, 2001;
MacDonald and Meakin, 1996; Perez et al., 1995; Wind-
isch et al., 1995a, 1995b; Zaccaro et al., 2001). Recently,
the crystal structure of NGF complexed to rat p75 re-
vealed an unusual asymmetric stoichiometry which left
one face of NGF open (He and Garcia, 2004). This obser-
vation raised the question of whether this open face could
engage a TrkA ECD to from a TrkA/NGF/p75 ternary com-
plex. Since the domains that were implicated in mediating
TrkA/p75 interactions were not included in the original
NGF/TrkA-D5 crystal structure, it has not been possible
to evaluate a structural model of the complete receptor
complexes.
In order to gain insight into the possible interaction of
TrkA and p75, we have solved the crystal structure of
the complete extracellular domain of TrkA complexed
with NGF and evaluate the possibility, through molecular
modeling, of a TrkA/NGF/p75 complex mediated by the
ECDs. To further investigate the prospect of a TrkA-p75
complex on a cell surface, we employed a recently devel-
oped enzyme complementation system to detect protein
interactions that can be performed on intact cells, in which
the receptor transmembrane (TM) domains are included
(Wehrman et al., 2005). Finally, we employed Scatchard
analysis of cells transduced with similar levels of TrkA
and p75, as well as the neuronal cell line PC12, to investi-
gate the presence of high-affinity binding sites. In sum-
mary, the structural and cellular data collectively point to
an alternative mechanism of TrkA/p75 communication
than one involving direct receptor-receptor interaction orthe formation of a ternary complex.
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Structure of the TrkA Ectodomain Complex with NGF
Crystals of the complex between the TrkA ECD and
human NGF were prepared using a soluble, baculovirus-
expressed human TrkA ectodomain (residues 33–423)
and recombinant human NGF expressed from E. coli.
Although the crystals diffracted to moderate resolution,
we avoided strategies to deglycosylate TrkA in order to
improve diffraction since there have been reports that
TrkA Asn-linked glycosylation can regulate its bioactivity
(Watson et al., 1999). The NGF homodimer and the TrkA
Ig-C2 domains in the complex were located by molecular
replacement, whereas the remaining domains of TrkA
were traced into electron density maps calculated using
partial phases from the NGF/TrkA-Ig-C2 model (Table 1).
The asymmetric unit contains a full 2:2 NGF/TrkA com-
plex. The final TrkA structure in the refined model contains
the leucine-rich repeats capped with cysteine-rich
domains (D1, D2, and D3 domains, respectively) and the
Ig-C1 and Ig-C2 domains (D4 and D5, respectively) (Fig-
ures 1A and 1B). Of the 13 possible N-linked glycosylation
sites in each TrkAmonomer, six high-mannose-containing
N-linked glycosylation sites were clearly defined in the
electron density in each receptor (Asn95, Asn121, Asn188,
Asn262, Asn281, Asn358) (Figure 2 and Figure S1). The
high-mannose carbohydrate moieties appear to play a
role in the TrkA structural integrity, as several are located
at TrkA interdomain boundaries. However, they do not
contact the ligand andwould therefore appear to influence
TrkA activation only indirectly.
Table 1. Crystallographic Statistics
Data Collection
Wavelength (A˚2) 1.0597
Resolution (A˚2) 50–3.4 (3.5–3.4)
Completeness (%) 99.0 (97.3)
I/s (I) 9.2 (2.4)
Redundancy 4.8 (4.7)
Rmerge (%) 8.3 (34.9)
Model Building and Refinement
Resolution range (A˚2) 50–3.4 (3.5–3.4)
No. of reflections 26668
Rcryst 0.297 (0.370)
Rfree 0.331 (0.391)
Average B factor (A˚2) 45.2
R.m.s.d. bond length (A˚) 0.008
R.m.s.d bond angle,
dihedral, improper ()
1.6, 25.5, 0.9
Ramachandran (favored, allowed,
generous, disallowed) (%)
71.9, 23.0, 5.1, 0
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Structural Biology of Neurotrophin ReceptorsFigure 1. Structure of Nerve Growth Factor Complexed with the Extracellular Domain of TrkA
Two side views as the complex would appear on the cell surface, shown rotated approximately 90 in the vertical plane. The TrkA ECDs are in orange
and shown as ribbons with transparent molecular surface, and NGF is blue/green and only shown as ribbons. N-linked glycosylations observed in the
structure are drawn as cyan surfaces. The approximately 32 amino acid connecting peptide linking the base of the Ig-C2 domain of TrkA to the cells
surface is drawn as dotted line. Cell membrane is depicted as a rectangular box.The overall structure of the NGF/TrkA complex is strik-
ing in appearance, vaguely reminiscent of a crab with
extended pinchers (Figure 1). The crab body is composed
of the NGF homodimer and is flanked by the pinchers,
comprised of the TrkA D1-D5 domains. This portion of
the complex shows no substantial deviations from the
previous truncated complex structure (Wiesmann et al.,
1999). The TrkA molecules, which contain the previously
missing N-terminal D1-D4 domains as well as the previ-
ously solved TrkA Ig-C2 (i.e., D5) domain, project upward
and away from the centrally located NGF (Figure 1A). The
C-terminal Ig-C2 domain of TrkA engages the sides of the
NGF homodimer, as previously shown. One copy of a TrkA
ECD binds to each side of NGF homodimer, confirming
the originally determined 2:2 stoichiometry of the NGF/
Ig-C2 complex. The long axis of TrkA is roughly parallel
to the long axis of NGF. TrkA is about 105 A˚ long and
30 A˚ in width, and the complex displays essentially perfect
2-fold symmetry through the NGF dyad axis. Collectively,
the TrkA receptor ECD adopts an almost coiled helical
structure due to the interdomain twists (Figure 1B).
In the TrkA structure (Figure 2A), the leucine-rich repeat
(LRR) D1D2D3 domains are essentially integrated as one
structural domain with a super-helical topology, display-
ing an elongated and curved shape with a length of 75 A˚
and width of 32 A˚. The TrkA D1D2D3 module is formed
by three LRR units (D2), flanked by two cysteine-rich do-
mains (D1 andD3), which have been defined as N-terminal
(LRRNT) and C-terminal (LRRCT) cap modules, respec-
tively. Three leucine-rich repeats form the central part of
the D1D2D3 body. Each repeat contributes one circleof the super-helix and is 25 residues long, with hydro-
gen-bonded turns as the interstrand segment between
repeats. Each of the interstrand segments contains a
half-turn of a-helix. The LRRCT contains a 13 residue
a-helix beginning and ending with short 310 helices (154–
164 and 169–173). These domains are conserved fea-
tures among most extracellular LRR proteins (Kobe and
Deisenhofer, 1994). For the rest of the discussion, we refer
to the entire D1D2D3 module collectively as the LRR,
unless otherwise specified.
The LRR forms intimate contact (approximately 750 A˚2
buried surface area) with the TrkA Ig-C1 domain (i.e.,
D4), which is a canonical C2 Ig-like domain with 4-on-3
b sheet sandwich topology, linked by a conserved disul-
fide (Cys215-Cys265) within the core (Figure 2B). There
is a twist in the boundary between LRR and Ig-C1 such
that they are related by about a 90 angle. The interface
between the LRR module and the Ig-C1 is unusual in that
a short linker peptide (187–192) connects the two domains
through a disulfide bond Cys154-Cys191. A substantial
amount of contact is also made between a hydrophobic
groove in the base of the LRRCT and the FG-loop of
Ig-C1. This interface is stabilized by a salt bridge (Glu268-
Lys133) and a hydrophobic cluster (Trp132, Trp158,
Ala155) surrounded by numerous van der Waals contacts.
The interdomain boundary is also augmented by an
Asn(188-)-linked glycan packing against Arg157 on the
LRRCT.
The base of the TrkA Ig-C1 domain forms extensive
interactions with the top of the Ig-C2 domain (approxi-
mately 700 A˚2 buried surface area), and they are alsoNeuron 53, 25–38, January 4, 2007 ª2007 Elsevier Inc. 27
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Glycosylated TrkA Extracellular Domain
(A) Complete ECD, in orange cartoon represen-
tation with Asn-linked glycosylations in cyan
space-filling representation. (B) The inter-
domain boundary between the LRR and Ig-C1
(D4) domain, indicating the position of the di-
sulfide bond that would constrain any hinge
movements. (C) The interdomain boundary
between Ig-C1 and Ig-C2 domains. Note: the
interdomain insets are not in the identical orien-
tation as panel (A) in order to achieve a clear
view of the interdomain boundaries. Panel (B)
has been rotated approximately 30 clockwise
into the plane of the page, and panel (C) has
been rotated approximately 90 counterclock-
wise out of the plane of the page.related to one another by an approximately 90 twist with
respect to the directions of the b strands (Figure 2C). The
interface is primarily composed of van der Waals contacts
formed by a hydrophobic cluster between the Ig-C1 EF-
loop (residues 255–261) and the Ig-C2 domain BC- (resi-
dues 306–310) and DE-loops (residues 337–341). Another
large Asn(281)-linked glycan from the base of the Ig-C1
domain packs into a groove on the side of the Ig-C2
domain, supplementing the already intimate interdomain
boundary. Thus, both the LRR/Ig-C1 and Ig-C1/Ig-C2
boundaries appear highly structurally constrained, and it
appears unlikely that large-scale conformational changes
would occur upon binding to NGF, as has been hypo-
thesized in an allosteric model of TrkA activation (Zaccaro
et al., 2001).
Of the five TrkA domains, only the C-terminal Ig-C2
domain interacts with NGF in the complex structure, as
originally seen in the truncated complex structure (Wies-
mann et al., 1999). The interaction between Ig-C2 and
NGF is rather striking in that the top loops of the Ig-domain
penetrate a saddle-like depression along the tops of
the NGF central b sheets, in an almost orthogonal fashion
(Figure 3B). As the NGF/TrkA-D5 interaction shows no
substantial deviations from the previous structure, we will
not describe the interface exhaustively.
One impetus for determining the structure of a full-
length TrkA ECD complex with NGF was that controversy
still persists over whether the Ig-C2/NGF complex repre-
sents the bona fide receptor complex, as several studies
have implicated additional N-terminal domains of TrkA in
NGF recognition (see Discussion) (Arevalo et al., 2000,
2001; MacDonald and Meakin, 1996; Perez et al., 1995;
Windisch et al., 1995a, 1995b; Zaccaro et al., 2001). The28 Neuron 53, 25–38, January 4, 2007 ª2007 Elsevier Inc.full-length TrkA ECD structure clearly shows that only
the Ig-C2 domain contacts NGF, and this observation
almost certainly extends to the other TrkA receptors (Fig-
ure 1) (Urfer et al., 1998). We have carried out companion
solution studies and find that the stoichiometry of this
complex is 2:2 even at saturating NGF concentrations, fur-
ther suggesting a single NGF binding site on TrkA (data
not shown). The structural and biochemical data strongly
argue for the fact that NGF does not contact any domains
in the TrkA ECD other than Ig-C2.
The second issue we hoped to gain some structural
insight into was whether there could be an interaction
between the ECD of TrkA and p75 in a putative ternary
complex with NGF. Numerous studies have suggested
that a direct interaction between TrkA and p75 is neces-
sary for the modulation of affinity and specificity observed
when both receptors are coexpressed (see Discussion)
(Hempstead et al., 1991; Lad et al., 2003; Mischel et al.,
2001; Zaccaro et al., 2001). Using information gained
from the structure of the full-length TrkA ECD, our inten-
tion was to assess the likelihood of a ternary complex of
Trk/NGF and p75.
We recently determined the structure of the rat p75
extracellular domain complexed with human NGF (He
and Garcia, 2004) (Figure 3A). This structure showed that
the NGF/p75 docking mode is completely different than
NGF/TrkA (Figures 3A and 3B). The structure also dis-
played an asymmetric bindingmode inwhich only one side
of the NGF dimer was bound to p75 (Figure 3A). The asym-
metric stoichiometry was apparently induced by NGF
binding and was verified as a stable entity in solution (He
and Garcia, 2004). A recent study has suggested that this
1:2 complex could be an intermediate on the path toward
Neuron
Structural Biology of Neurotrophin Receptorsformation of a stoichiometric 2:2 complex, but this has not
been unequivocally demonstrated (Aurikko et al., 2005).
One explanation for the 1:2 stoichiometry and asymmetry
of the NGF/p75 complex crystal structure was to maintain
Figure 3. Comparative Structural Analysis of NGF/p75 and
NGF/TrkA Complexes
(A) The structure of NGF complexed to p75 (He and Garcia, 2004) and
the neighboring complex of NGF with TrkA. The polarity of NGF in the
two complexes is indicated with yellow arrows (pointing toward N and
C termini). The intracellular domains of both receptors are drawn sche-
matically. NGF is depictedwithmolecular surfaces, while p75 and TrkA
are shown as ribbons. Note the open face of NGF on the asymmetric
p75 complex that could represent a potential binding site for a single
TrkA ectodomain in a scenario where p75 and TrkA existed as an equi-
librium of intermediate homo- and heterocomplexes on the cell sur-
face. (B) The binding sites of NGF on p75 and TrkA are mutually exclu-
sive on the same face of NGF, but the binding footprints are largely
nonoverlapping on the NGF surface. The red and yellow patches on
NGF indicate the portions of the binding surface on each NGF mono-
mer; note how both Trk and p75 contact both halves of the homodimer.
(C) A ternary complex of a p75/NGF/TrkA 1:2:1 heterotrimer is steri-
cally feasible if the receptors lie parallel to the membrane in order to
sandwich NGF between them in antiparallel orientations. The closest
point of approach between p75 and TrkA is between the base of the
p75 ECD and the LRR of TrkA, where they are within 20 A˚ reach.an open face of NGF for formation of a ternary complex
with TrkA (He and Garcia, 2004). Importantly, the confor-
mational changes induced in NGF by p75 did not extend
to its TrkA binding surface. Now, with structures of both
NGF/p75 and NGF with full-length TrkA ectodomain, we
can model a ternary complex.
When modeled on the cell membrane and compared
side by side, two features are apparent. First, NGF binds
to TrkA and p75 in opposite orientations (Figure 3A).
When bound to TrkA, the ‘‘head’’ of NGF (N and C termini)
is membrane proximal, but when bound to p75, the head
is membrane distal. Therefore, TrkA and p75 will be in an
antiparallel orientation if both are simultaneously bound to
NGF. Second, TrkA and p75 interact with NGF through
nonoverlapping binding sites that are on the same face
of NGF. p75 forms a two-point attachment along protrud-
ing surfaces of the NGF homodimer by docking within
a groove between monomers (Figure 3B). In contrast,
TrkA-D5 binds within the saddle of NGF, between the
protruding surfaces used by p75 (Figure 3B). Even though
the ‘‘footprint’’ of the binding sites are largely nonoverlap-
ping, p75 and TrkA would sterically obstruct one another
from binding simultaneously to the same face of NGF.
Therefore, in accord with the modeling studies of Aurikko
et al., there does not appear to be a possibility of a 2:2:2
symmetric tricomplex of TrkA/p75/NGF (Wiesmann and
de Vos, 2001). However, p75 and TrkA can bind to oppo-
site sides of NGF simultaneously to form a 1:2:1 ternary
complex without any steric clashes (Figure 3C).
Given the two constraints mentioned above (antiparallel
orientation andmutually exclusive binding sites onNGF), it
is sterically possible to construct a ternary complex (Fig-
ure 3C). However, this cannot be accommodated if the
receptors both extend straight up from the cell surface
but can be easily accommodated if they lie parallel to
the membrane, sandwiching NGF between them. There
is ample precedent for receptors engaging ligand parallel
to the membrane (Chow et al., 2001), and this is spatially
possible for TrkA and p75 since they both have extended
connecting peptides linking the ECD to the cell surface
that likely permit flexibility. In this ternary complex, the
TrkA N-terminal LRR is nearest to the C-terminal base
(CRD1) of p75, but the domains are separated by approx-
imately 20 A˚ (Figure 3C). Direct contact between the re-
ceptors would require a rotation of the LRR around the
linker connecting it to the D4 domain. As the interdomain
hinges appear constrained by a disulfide bond (Figure 2B),
we are skeptical whether such a conformational change
would occur to result in p75/TrkA contact.
We have been unable to produce a stable TrkA/p75/
NGF ternary complex in solution. One possible explana-
tion for this is that the transmembrane regions of the re-
ceptors play a role in p75/TrkA interactions, and they are
missing in the soluble ECD constructs, as suggested in
one study. Therefore, we decided to assess TrkA/p75
interactions on living cells in a format in which the TM
segments are preserved, as well as portions of the intra-
cellular domains.Neuron 53, 25–38, January 4, 2007 ª2007 Elsevier Inc. 29
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To determine potential interactions of TrkA and p75 in in-
tact cells, we utilized a previously described complemen-
tation system of b-galactosidase to address this question
(Wehrman et al., 2005, 2006). The general principle is that
b-galactosidase is split into two inactive fragments, a small
fragment (a) and a larger fragment (u), which, when fused
to two proteins that interact, reconstitute into an intact
enzyme with activity that can be easily measured by lumi-
nescence (e.g., Figures 4A and 5A). This b-gal method is
a weakly complementing protein interaction system (i.e.,
low background activity) wherein the enzyme activity is
directly proportional to the local concentration of the two
enzyme fragments. The system was first used to monitor
changes in local protein concentration associated with
intracellular protein movement (protein translocation)
(Wehrman et al., 2005, 2006). As the concentration of a*
oru increases, the enzyme activity increases accordingly.
A significant advantage of enzyme complementation over
studies using purified proteins or coimmunoprecipitation
is that the receptors remain in the two-dimensional con-
text of the plasma membrane as opposed to the three-
dimensional environment obtained in solution or in cell
lysates. Most importantly, a specific binary interaction of
a* and u is necessary to obtain b-galactosidase activity,
thus providing a direct ‘‘molecular’’ or ‘‘stoichiometric’’
assessment of the protein-protein interaction. This feature
of the technique differs substantially from co-IP and
crosslinking, which assess the proximity of neighboring
molecules that could be associated for reasons other
than a specific interaction.
The ECD and TM regions of TrkA (TrkA) and p75 as well
as the full-length p75 (p75FL) were each fused to the N ter-
minus of u and YFP-H31R a-peptide fusion (a*). Since
TrkA is efficiently internalized upon activation, if the full-
length TrkA receptor were used in the b-gal system, then
the internalization would result in an artifactual decrease
in the concentration of the receptors at the plasma mem-
brane and thus result in a change in b-gal activity indepen-
dent of ligand interaction. In order to avoid modulation of
b-gal activity that was not associated with receptor inter-
action, we utilized a truncated TrkA receptor that elimi-
nates the internalization motifs. In contrast, p75 is not
actively internalized, so both full-length and truncated ver-
sions of the receptor could be studied. Therefore, all of the
constructs in these experiments contain at least both ECD
and TM regions, which have been implicated in mediating
the TrkA/p75 interaction (Esposito et al., 2001; Mischel
et al., 2001). Prior to these experiments we ascertained
that C2C12 cells do not express significant amounts of
p75 by Western blotting untransfected C2C12 cells and
comparing to the transfected C2C12 cells (Figure S3).
TrkA is well known to homodimerize in the presence of
NGF; thus we determined whether this interaction could
be measured using b-gal complementation. A stable cell
line containing the TrkAu and TrkAa* fusion constructs
was generated by retroviral infection of C2C12 cells
(Figure 4A). Cells were plated into a 96-well dish and as-30 Neuron 53, 25–38, January 4, 2007 ª2007 Elsevier Inc.sayed in triplicate for changes in b-gal activity in the pres-
ence of NGF. Addition of NGF to the medium increased
b-gal activity by greater than 250%, indicating robust
Figure 4. Homodimerization of TrkAMonitored inMammalian
Cells using b-Gal Complementation
(A) The low-affinity b-gal complementation system consists of a
mutated a peptide (a*) and the traditional u fragment that are fused
to the two proteins that interact. Interaction of the two proteins results
in an increase in enzyme activity.
(B) C2C12 cells expressing TrkA-a* and TrkA-u were exposed to in-
creasing doses of recombinant NGF, and b-gal activity was measured
using a chemiluminescent substrate.
(C) A time course of TrkA homodimerization was obtained by exposing
the cells to 1 mg/ml NGF at different times.
Error bars represent one standard deviation.
Neuron
Structural Biology of Neurotrophin ReceptorsFigure 5. The Interaction of TrkA with p75 Is Not Detectable using b-Gal Complementation in the Presence or Absence of Ligand
(A) The cell lines constructed with the indicated receptor pairs are shown as fusions to the a* and u fragments.
(B) To control for protein expression levels, a parental cell line was constructed that stably expressed TrkA-u. This line was transduced with the
TrkA-a*, p75a*, and EGFRa*. Because each a* construct contains YFP inserted between the receptor and the a*, cells were sorted by FACS for similar
expression levels.
(C) The localization of each of the a* constructs must be similar in order for the flow cytometry data to be an accurate representation of the protein
expressed at the cell surface. Transfection of the a* constructs into HEK293 cells shows a similar membrane staining pattern for all of the receptor
fusions.
(D) The cells expressing each of the receptor pairs were plated at the same density in a 96-well dish and assayed for b-gal activity in the presence and
absence of 1 mg/ml NGF. Each cell line was assayed in triplicate with error bars representing one standard deviation. The TrkA is shown to homo-
dimerize efficiently, whereas both the control cell line, TrkA-EGFR, which should not interact, and the TrkA-p75 line both show a decrease in
b-gal activity in the presence of NGF, presumably due to homodimerization of the TrkA that reduces the basal enzymatic activity obtained. The basal
enzyme activity for each cell line is similar, indicating similar levels of spontaneous interaction for all receptor pairs tested.homodimerization of TrkA. This effect is dose and time
responsive, demonstrating specificity of the reaction (Fig-
ures 4B and 4C).
Mechanistically, TrkA and p75 could cooperate in many
different ways. The proteins might assemble spontane-
ously and dissociate in the presence of ligand, or hetero-
meric complexes could form as a result of ligand binding.
Because the stochiometry and inducibility of a p75-TrkA
complex is unknown, it was necessary to study NGF-
induced changes in protein interaction as well as basal
levels of dimerization. In order to design a system that
couldmeasure background aswell as induced interaction,
we normalized the expression level of the fusion proteins
because the overall enzyme activity derived using the
b-gal system is sensitive to the expression levels of the
two enzyme fragments. To control for fusion protein ex-
pression levels, a parental cell line was constructed stably
expressing TrkAu. The cell line was then transduced with
EGFRa*, TrkAa*, and p75a* (Figure 5A). YFP was included
between the receptor domain and the a* to enable selec-
tion of cells expressing similar levels of a* by FACS and
to present the a peptide similarly in all fusion proteins.
Because each cell line is derived from the same parentalpopulation, the levels of u are equivalent. FACS was used
to sort for YFP expression, which correlates with expres-
sion of the a* (Figure 5B). In this manner the expression
of each of the b-gal fusions has been normalized. In order
for the total YFP fluorescence to accurately reflect
the concentration of the a* fusions, the proteins must be
similarly localized. Transfection of each construct into
HEK293 cells shows a predominant membrane localiza-
tion for all constructs tested (Figure 5C).
The resulting three cell lines were plated at the same
density in a 96-well dish and assayed for b-galactosidase
activity in the absence and presence of NGF. The back-
ground activity of the system is defined by the amount
of signal generated from the noninteracting protein pair,
TrkAu-EGFRa, which results from a weak spontaneous
complementation of the fragments. As expected, the
TrkAu-TrkAa* cell line showed an increase in enzyme
activity induced by the presence of NGF. The background
activity of this cell line and the TrkAu-p75a* is similar to
the control TrkAu-EGFRa* cell line, indicating little, if any,
basal dimerization of these receptors (Figure 5D).
The EGFR-TrkA cell line shows no induction in the pres-
ence of NGF, nor does TrkA and p75, demonstrating thatNeuron 53, 25–38, January 4, 2007 ª2007 Elsevier Inc. 31
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ciation Is Not Affected by NGF Binding
(A) Parental cell lines were created using the full-length (p75FL) and
truncated (p75) forms of the p75 receptor fused to the u. The parental
cell lines were trasnduced with the indicated a* fusion proteins and
sorted for similar YFP expression levels as a measure of the a* present
in each line.
(B)Cells expressing the indicatedb-gal receptor fusionswere assessed
for their basal enzymatic activity. Each cell line is shown as a fold
increase over the control cell line which should not interact (EGFR-
p75), with error bars representing one standard deviation. The lines
expressing either a truncated or full-length p75 show a 2-fold higher
b-gal activity than the control EGFR-p75 cell lines, indicating that
p75 homo-oligomerizes. Both the truncated and full-length receptors
show similar levels of enzyme activity, demonstrating that the extra-
cellular and transmembrane domains are sufficient for the interaction.32 Neuron 53, 25–38, January 4, 2007 ª2007 Elsevier Inc.p75 and TrkA do not inducibly form heterodimers. In both
the TrkAu-EGFRa* and TrkAu-p75a* cell lines, a modest
decrease in enzyme activity is observed. The loss of
enzyme activity suggests that NGF is homodimerizing
the TrkA fusion and thus removing TrkA from the pool,
therefore limiting the basal interaction of the TrkAu-
p75a* enzyme fragments. Because no induction of en-
zyme activity was observed for the p75 construct, we con-
firmed that cells expressing p75 were able to bind NGF
using a fluorescently labeled NGF (Alexa 647) and analysis
by flow cytometry (Figure S2). As previously mentioned,
we also verified that C2C12 cells do not express levels
of endogenous p75 that would effect the b-gal readout
(Figure S3). These data provide evidence for an NGF-
inducible interaction of TrkA homodimers, but not TrkA
and p75 heterodimers.
Homotypic p75 Interactions
Several reports have shown that NGF binding to p75 initi-
ates an apoptotic cascade in the absence of TrkA (Frade
et al., 1996; Majdan et al., 1997), although the molecular
basis of this observation remains unclear. Although TNF-
family death receptors normally exist as trimers, quiescent
p75 has been shown by crosslinking to exist as a dimer
on the cell membrane (Grob et al., 1983). Binding of
NGF to p75 has been variously proposed to induce the di-
merization of p75 (Wang et al., 2001) or disrupt preformed
p75 dimers (Wang et al., 2000) or form a range of receptor-
ligand stoichiometries (Aurikko et al., 2005; Ibanez et al.,
1992). To address changes in oligomerization of p75 by
NGF, we first determined the basal oligomerization state
of p75 by constructing six cell lines expressing pairwise
combinations of the p75 (truncated), p75fl (full-length),
and EGFR fused to the a* and u b-galactosidase enzyme
fragments. Parental cell lines were constructed using the
p75flu and p75u. The p75a*, p75fla, and EGFRa were
then introduced into these cell lines (Figure 6A). Cells
were sorted for similar YFP expression levels and plated
at the same density in a 96-well dish. Enzyme activity
was measured in the absence of NGF. For each parental
cell line, the enzyme activity resulting from the EGFR
construct was placed at a value of 1, and the activity of
the other cell lines was expressed as a fold change (Fig-
ure 6B). All cell lines expressing either p75 or p75fl fused
to the a* and u generate greater than 200% of the activity
of the cell lines containing the EGFR. These results sug-
gest that p75 at least oligomerizes in the absence of
ligand, in accord with previous studies using purified pro-
teins or immunoprecipitation (He and Garcia, 2004; Jing
et al., 1992). Therefore, membrane-bound p75 full-length
(C) The truncated p75 and full-length p75 homodimerization cell lines
were tested for a change in association in the presence of the ligand
NGF. As controls, the TrkA homodimerization cell line was included
and shows a robust homodimerization. Similar to what was observed
previously, the TrkA-p75 cell line showed a modest decrease in b-gal
activity in the presence of NGF. Addition of NGF had no effect on the
enzyme activity obtained from the p75 homodimerization cell lines.
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ECD (He and Garcia, 2004).
In order to test the ability of NGF to disrupt preformed
oligomers, the p75 homodimerization cell lines were com-
pared to the TrkA homodimerization and TrkA-p75 heter-
odimerization cell lines (Figure 6C). Cells were treated with
various concentrations of NGF for 45 min and then as-
sayed for changes in b-gal activity. In the presence of
NGF, the TrkAu-TrkAa* cell line shows a dose-dependent
increase in enzyme activity as expected, and the TrkAu-
p75a* cell line shows a decrease in activity as shown
earlier. The p75 homodimerization cell lines show no sig-
nificant change at any dose tested, indicating that NGF
does not change the oligomerization state of the receptor,
despite binding to the ECD (Figure S1).
Scatchard Analysis of Cells Expressing p75 and TrkA
The results from the biochemical studies failed to support
the physical association of soluble TrkA and p75 ECDs.
The enzyme complementation data confirmed the exis-
tence of p75 oligomers and NGF-induced TrkA homodi-
merization, but a basal or induced interaction of p75
with TrkA was not observed. To further explore this possi-
bility, we performed radiolabeled binding studies of NGF
to cells transduced with TrkAa* and p75a*. Western blot
using an antibody against GFP shows that the cell line ex-
presses similar amounts of each protein (Figure 7A). Cells
were treated with increasing doses of 125i NGF, and the
amount of bound and free ligand was determined (see
Experimental Procedures). The reported number of high-
affinity binding sites for NGF ranges from 5%–15% of
the total NGF binding. Thus, to achievemaximum sensitiv-
ity, subsaturating doses of NGF were used (0.00001 to
1 nM/100,000 cells). The saturation binding curve indi-
cates a Kd of 0.9 nM ± 0.3 in good agreement with the
published values of the ‘‘low-affinity’’ NGF binding site,
which is equivalent to binding to p75 or TrkA alone. The
data were analyzed using nonlinear regression of one-
site and two-site binding models (Figure 7B). The data
could only be fit by a one-site binding isotherm yielding
an r2 value of 0.9733. Background-subtracted Scatchard
transformation of the binding data also shows a single
linear relationship (Figure 7C). By comparison, the same
datawithout a background subtraction shows a curvilinear
plot (Figure 7D) with a trend upward at low ligand concen-
tration, similar to that observed for the classical high-affin-
ity site. Therefore, we can reproduce a two-site model by
performing the Scatchard analysis without a background
correction. We also performed background-subtracted
Scatchard analysis of C2C12 cells transfected with full-
length p75 and truncated TrkA alone and find the same
single-site result as for the cotransfected TrkA/p75 cells
(Figures 7E and 7F). In order to test whether the modified
Trk and p75 constructs in the transfected cells used for
Scatchard analysis were responsible for the absence of
the high-affinity site, we also carried out Scatchard analy-
sis of a neuronal cell line, PC12, which express endoge-
nous full-length p75 and TrkA (Figure 7G). Again, we failto detect a high-affinity binding site by Scatchard transfor-
mation of the equilibrium binding data and instead deter-
mine a single affinity for NGF of approximately Kd 1 nM.
One of the problems we and others (Klotz and Hunston,
1984; Nekhai et al., 1997; Nicosia, 1988; Zierler, 1989)
have observed in performing Scatchard tranformation of
binding data is that at low values the Scatchard manipula-
tion is highly sensitive to errors in background calculation.
As the values decrease, the scatter of the data points
is not random but has a trend upward approaching a
Figure 7. Scatchard Analysis of TrkA and p75 on Transfected
and Neuronal Cells
(A) Western blot analysis of C2C12 cells expressing the indicated a*
fusion proteins. The TrkAa*-p75a* cell line was used in the binding
studies.
(B) Saturation binding curve of radiolabeled NGF binding to the TrkAa*-
p75a* cell line.
(C) Scatchard transformation, with background subtraction, of the
binding data shown in (B).
(D) Scatchard transformation of the binding data without subtracting
the background signal.
(E) Scatchard analysis of truncated TrkAa* alone showing single-site
binding.
(F) Scatchard analysis of full-length p75a* alone showing single-site
binding.
(G) Scatchard analysis of PC12 cells showing single-site binding.
Error bars represent one standard deviation.Neuron 53, 25–38, January 4, 2007 ª2007 Elsevier Inc. 33
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(Figure 7D). For this and other reasons, Scatchard trans-
formation of data for radiolabeled ligand binding has been
discouraged and largely replaced with nonlinear transfor-
mation of saturation binding data.
DISCUSSION
Our goal in this report was to (1) clarify the structural biol-
ogy of NGF/TrkA interactions and (2) probe a molecular
basis for the apparent communication between p75 and
Trk receptors. Since the discovery that NGF could bind
two separate transmembrane receptor systems present
on the surface of a single neuronal cell, elucidating the in-
terplay of these molecules in neuronal signaling has been
enigmatic. The literature bearing on this topic is vast, but
so far inconclusive. Although most studies are in agree-
ment that both TrkA and p75 play a role in NGF signaling,
the mechanism by which p75 influences TrkA signaling
remains unclear. Many published studies, citing several
lines of functional, cellular, and structural evidence, pro-
pose that the receptors themselves may physically inter-
act or communicate through allostery (summarized in
Introduction) (Bothwell, 1995; Lad et al., 2003; Mischel
et al., 2001; Yano and Chao, 2000). On the other hand,
these data are contradicted by several studies showing
that p75 has no influence on Trk binding affinity (Aurikko
et al., 2005; Bothwell, 1995; Jing et al., 1992).
Since the ligand binding of both Trk and p75 are dic-
tated by their extracellular domains, and the various
Trk(A, B, or C)/p75 high-affinity binding sites are neurotro-
phin-specific, involvement of these domains would seem
a necessary prerequisite to explain the effects of p75 on
Trk ligand binding, as suggested (Lad et al., 2003). We first
addressed whether additional extracellular domains of
TrkA, not included in an earlier NGF complex with a single
Ig-C2 domain of TrkA, could influence NGF recognition
or interaction with p75. It has been proposed that neuro-
trophins interacted with the LRR domain of TrkA
(MacDonald and Meakin, 1996; Windisch et al., 1995a,
1995b), and Zaccaro implicates both the LRR and Ig-C1
domains, in addition to Ig-C2, as being necessary for NT
activation of TrkA and coordination with p75 (Zaccaro
et al., 2001). Zaccaro further proposes a model whereby
TrkA contains ‘‘high’’ and ‘‘low’’ affinity NGF binding sites
on the ECD that are regulated allosterically through TrkA
conformational changes, such as interdomain rotations.
From the structure presented in this paper, it is clear
that NGF only interacts with the TrkA-D5 domain, con-
sistent with several structure-function studies using re-
combinant NGF and TrkA Ig-C2 domain (Urfer et al.,
1998). With regards to potential NGF-induced allostery
in TrkA, the domains of TrkA are associated with each
other through large and constrained interdomain inter-
faces—including a disulfide bond between the LRR and
Ig-C1 domains. It would be energetically costly to disrupt
these boundaries in order to undergo significant con-
formational changes, although in the absence of an34 Neuron 53, 25–38, January 4, 2007 ª2007 Elsevier Inc.unliganded TrkA structure we cannot completely rule out
this possibility.
With the structure of the complete NGF/TrkA ECD com-
plex in hand, we can now address the issue of TrkA com-
munication with p75 with adequate structural models.
Recently, the structure of p75 bound to NGF was re-
ported, in which only a single p75 molecule was bound
to one side of the NGF homodimer, leaving one face of
NGF open. Conceptually, this complex structure was con-
sistent with the observation that p75 coordinates with
numerous different cell surface receptors to transduce
signals in a variety of neuronal settings, such as Nogo
receptor, Sortilin, and Trk (Barker, 2004). p75 and Trk
could exist in a dynamic equilibirium of transient homo-
and heterodimeric complexes, depending on the relative
concentrations of each, that is controlled through confor-
mational changes of p75 and Trk, as others have also sug-
gested (Aurikko et al., 2005; Ibanez et al., 1992). From the
structure of the TrkA full-length extracellular domain we
see that TrkA and p75 have different binding footprints
on NGF, but their binding sites overlap in a way that
prevents both from binding simultaneously on the same
side of NGF to form a 2:2:2 complex, as wasmodeled pre-
viously (Wiesmann and de Vos, 2001). Althoughwe cannot
detect association between soluble p75 and soluble TrkA
ECD, the plasma membrane may be necessary for this
interaction (Esposito et al., 2001).
To maintain the native state of the receptors in the
plasma membrane and test the contribution of the trans-
membrane regions to the interaction, we used a recently
developed enzyme complementation system designed
to detect reversible protein-protein interactions in intact
cells (Wehrman et al., 2005, 2006). Using this technique
we show that the ECD and TM regions of TrkA are suffi-
cient tomediate homodimerization in the presence of NGF
as expected. Both truncated and full-length p75 were
found to exist in a multimeric form both in the presence
or absence of NGF, similar to findings in cells (Grob
et al., 1983; Jing et al., 1992). This latter result suggests
that the mechanistic role of NGF in p75 activation may
be to perturb or alter the preformed dimer orientation in
order to initiate intracellular signaling, rather than disrupt
it. However, we were unable to find evidence for the for-
mation of a p75 and TrkA heterodimer.
The results from all three approaches point to the fact
that the ECD and TM domains of these receptors are in-
sufficient to mediate their interaction. Because these re-
sults were surprising given the biological evidence for
the interaction, we revisited the traditional radiolabeled
NGF experiments to determine if the ECD and TMportions
of these molecules were sufficient to form the high-affinity
binding site. Binding of NGF to cells expressing both TrkA
and p75 in our experiments showed a saturation binding
curve that only fit a single-site model using nonlinear
regression with the expected equilibrium binding constant
of the ‘‘low-affinity’’ site. Scatchard transformation of
the data for which we carried out a background correc-
tion also failed to reveal the presence of the reported
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pothesis that the extracellular and transmembrane
domains of Trk and p75 give rise to only a single class of
low-affinity binding sites. We also carried out Scatchard
analysis with background correction for C2C12 cells indi-
vidually transfected with full-length p75 and truncated
TrkA (Figures 7E and 7F). Again, we do not detect
a high-affinity biding site, rather wemeasure an NGF affin-
ity of approximately 1 nM, which is similar to that of p75
and TrkA alone for NGF. Finally, in order to account for
the possibility that the modified Trk and p75 constructs
we used for transfection were in some way artifactually
prevented from forming a high-affinity site, we carried
out NGF binding Scatchard analysis on PC12 cells ex-
pressing endogenous (and by definition full-length) p75
and TrkA, and we still do not detect the high-affinity site,
but rather a single site with an affinity of1 nM (Figure 7G).
Coimmunoprecipitation results have also suggested an
interaction of TrkAwith p75. One study showed that the in-
teraction of p75 and TrkA was only detectable if Trk was
immunoprecipitated using antibodies to the intracellular
domain and not using antibodies to the extracellular do-
main. (Lad et al., 2003). Since TrkA is efficiently internal-
ized in the presence of NGF, one plausible explanation is
that the observed interaction comes from the immunopre-
cipitation of intact endosomes that are contaminated with
p75, as it is not actively excluded from the endosomal
compartment. Antibodies that recognize the extracellular
domain of TrkA would fail to immunoprecipitate this frac-
tion and thus failed to coimmunoprecipitate p75. Impor-
tantly, the assays employed in our work using enzyme
complementation utilize a specific bimolecular interaction
of a* and u. In order to achieve changes in enzyme activ-
ity, the a* and u fragments must interact directly, provid-
ing a more stringent analysis of protein interactions than
coimmunoprecipitation experiments where fragments of
plasma membrane or endocytic vesicles which contain
both receptors will result in positive signals.
Perhaps the most compelling evidence for the collabo-
ration of Trk and p75 stems from the biological observa-
tion that expression of both Trk and p75 enhances and
sensitizes neurons to neurotrophin signaling. The pres-
ence of the high-affinity binding site for Trk and p75 pro-
vides a convenient explanation for the ability of neurons
to respond to low concentrations of neurotrophin. How-
ever, the high-affinity binding site is consistently reported
to be 1003 higher than the low-affinity binding observed
for either TrkA or p75 alone, whereas the difference in cel-
lular response to NGF is only on the order of 1.5- to 3-fold.
The discrepancy in the affinity versus responsiveness im-
plies that saturation of the high-affinity binding site in tis-
sue culture cells is not sufficient to mediate a significant
cellular response in vitro. In vivo, NGF is also present at
extremely low concentrations and, yet, initiates signaling
which again suggests a role for the high-affinity binding
site. An explanation for this phenomenon can be derived
from elegant work showing that Trk homodimers are
capable of being internalized and continued signaling inthe endosome (Howe and Mobley, 2005; Riccio et al.,
1997). The concentration of NGF in the endosome is suffi-
cient to saturate the ‘‘low-affinity’’ binding sites, thus cre-
ating a prolonged signaling effect. The extraordinarily slow
off rate of the TrkA/NGF complex creates a system that
can maintain a prolonged response to very low levels of
ligand using only the described low-affinity binding sites.
The number of active receptors necessary to transmit a
biological response remains to be determined, but the un-
usual sensitivity of the system might be explained by the
stability of the TrkA signaling complex in the endosomes
rather than saturation of the high-affinity binding sites.
Taken together, our structural, biochemical, andmolec-
ular data argue against a direct structural ‘‘collaboration’’
between p75 and TrkA in forming the high-affinity NGF
binding site. However, they do not exclude the possibility
that a high-affinity NGF binding complex exists. The struc-
tural data presented here discourage the possibility of an
allosteric modulation of the extracellular domain of TrkA,
but other mechanisms such as clustering of receptors in
lipid rafts or the participation of other associated proteins
may account for the observed alterations in NGF affinity.
In principle, if TrkA and p75 were tethered to the cytoskel-
eton or the same intracellular adaptor molecule (Chang
et al., 2004), it could result in an avidity effect that might
appear as higher-affinity binding.
Alternatively, a model of convergent signaling between
these two unrelated receptors could explain the down-
stream biological observations. The signaling molecules
activated by TrkA are typical of conventional trophic sig-
nals transduced by receptor tyrosine kinases, such as
activation of the MAPK and PI3-kinase pathways. By con-
trast, the list of proteins and pathways activated by p75
is much more extensive. At least nine proteins are thought
to interact with the intracellular domain of the receptor that
mediate apoptotic (Khursigara et al., 1999; Ye et al., 1999)
as well as prosurvival signals (Lachyankar et al., 2003;
Nykjaer et al., 2005; Roux et al., 2001). In addition, p75 is
known to activate nf-kappaB (Burke and Bothwell, 2003;
Carter et al., 1996;Hamanoueet al., 1999) and jnk (Harring-
ton et al., 2002; Majdan et al., 1997). The variety of sig-
naling molecules influenced by p75 makes it likely that
crosstalk between these and TrkA effectors mediate the
pleiotropic biological effects of p75 (Yeiser et al., 2004).
In support of this hypothesis, it has been shown that sep-
arate populations of cells expressing both p75 and Trk
respond differently to NGF, suggesting that the specific
profile of intracellular mediators (Bilderback et al., 2001;
Casademunt et al., 1999; Yeiser et al., 2004) may dictate
the phenotypic response and sensitivity toNGF rather than
physical collaboration of p75 and TrkA in NGF binding.
EXPERIMENTAL PROCEDURES
Cloning and Expression
Recombinant human nerve growth factor, expressed and refolded
from E. coli, is a gift from Genentech, Inc. (A.M de Vos). The human
TrkA receptor was produced using the baculovirus system in insectNeuron 53, 25–38, January 4, 2007 ª2007 Elsevier Inc. 35
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ing sequence for the full extracellular domain (residues 33–423) into
the pAcGp67A secretion vector (Pharmingen); 7-histidine tags were
appended to the COOH-termini. Recombinant baculovirus was pro-
duced and amplified using sf9 cells in serum-containing media. For
large-scale expression of the protein, 1 l of Hi5 cells were grown to
a density of 1.83 106 cells per milliliter in Insect-Xpress (BioWhittaker)
in a shaking Fernbach flask and were infected with recombinant virus
at an MOI of >10. Cultures were allowed to progress for 66 hr before
the cells were pelleted by centrifugation; the supernatant was concen-
trated and exchanged into a buffer of HBS (HEPES-buffered saline,
10 mM HEPES [pH 7.2], 150 mM NaCl), captured by Ni-NTA resin,
and then purified with gel-filtration chromatography (Superdex-200).
The NGF/TrkA complex was prepared by mixing excess amount of
NGF with TrkA and separating the complex from NGF by gel filtration.
For the cellular studies, the signal peptide, extracellular and trans-
membrane domains of human TrkA (nt 1-1344) aswell as the full-length
rat p75, and a version lacking the p75 intracellular domain (nt 1-861)
were amplified by PCR from cDNA. The portion of the EGFR utilized
was as previously described (Wehrman et al., 2006). An MfeI site
was included in the design of the 50 primers and an XhoI site was in-
cluded in the 30 primer. The resulting PCR products were cloned into
retroviral vectors to produce the N-terminal fusions to the u and
YFP-a fragments. The a* peptide vector has eYFP cloned as a fusion
N-terminal to the peptide (Wehrman et al., 2005).
Crystallization
For crystallization, the NGF/TrkA complex was concentrated to
10 mg/ml in HBS. The crystals were made through vapor-diffusion in
sitting drops containing equal volumes of protein and the well solution
containing 15% PEG20000, 1 M glycine, 0.15 M NaCl, buffered with
0.1 M HEPES (pH 7.5).
Data Collection and Processing
Data sets were measured on a 2 3 2 ADSC CCD at Beamline 11.1 at
the Stanford Synchrotron Radiation Laboratory (SSRL), Stanford.
Crystals were cryoprotected before cooling to 100 K with presence
of 20% ethelyne glycol in the mother liquor. The data set was collected
to 3.4 A˚. The crystals have a spacegroup P21, with cell dimensions
a = 110.22 A˚, b = 81.68A˚, c = 115.75 A˚. The data were indexed, inte-
grated, and scaled with HKL2000 (Otwinowski and Minor, 1997).
Model Building and Refinement
NGF dimer plus the TrkA-D5 was located by molecular replacement
with the structure of previously solved partial complex as a search
model. Phases calculated with the partial model were density-modi-
fied with CNS (Brunger et al., 1998). Although the partial model is
only 45% complete, the high solvent content (73%, Mathews coeffi-
cient 4.8) and the 2-fold NCS averaging helped to generate an electron
density map in which the rough positions of the LRR domain and the
Ig-like domain could be identified. A part of Nogo receptor LRR with
the C-terminal cysteine-rich domain and four repeats truncated was
then manually placed into the horseshoe-shaped electron density,
and the D4 Ig-like domain was placed similarly. Further 2-fold averag-
ing using the mask around the placed domains dramatically improved
the quality of the electron density map, and themolecular details of the
LRR repeats and the D4 b strands emerged, allowing the building of
a complete TrkA model.
The structure was refined using CNS (Brunger et al., 1998). Maxi-
mum-likelihood simulated annealing using the CNS torsion angle dy-
namics protocol was carried out. Throughout refinement, all reflection
data were used without sigma-cutoff. Repeated iterations between
manual rebuilding and minimization as well as B factor refinement
finally resulted in a model with converged R factor of 29.7% and Rfree
of 33.1%. A summary of the refinement statistics and the stereochem-
istry analysis is given in Table 1.36 Neuron 53, 25–38, January 4, 2007 ª2007 Elsevier Inc.Cell Line Creation
C2C12 myoblasts were obtained from laboratory stocks and grown in
DMEM (Invitrogen) 20%FBS (Hyclone) including penicillin and strepto-
mycin. The ecotropicFNX packaging cell line (P.L. Achacoso and G.P.
Nolan, personal communication) was transiently transfected with the
plasmid DNA constructs in 6-well dishes using lipofectamine transfec-
tion reagent (Invitrogen) according to manufacturer’s instructions. The
supernatant from the transfected cells was removed 24–72 hr later and
applied to C2C12 myoblasts. Polybrene was added to a final concen-
tration of 8 mg/ml (Sigma, St. Louis, MO). Transduced cells were
selected by FACS on a Becton Dickinson flow cytometer with MoFlo
electronics for YFP expression and/or by the addition of geneticin
(Invitrogen) at a concentration of 1 mg/ml.
b-Galactosidase Assays
Carriedout essentially asdescribed inWehrmanet al. (2005).Cellswere
plated at 20,000/well in 100 ml volume in white, clear-bottom 96-well
plates (Corning Costar, Acton, MA). Media was aspirated and b-galac-
tosidase activity was assayed by addition of GAL-Screen substrate
(50 ml total volume of a 1:25 solution B to solution A ratio) (Applied Bio-
systems, buffer B formulation), and the plates were incubated at RT for
40 min. Luminescence was measured in a Tropix TR717 luminometer.
Scatchard Analysis
Cells expressing the Trka* and p75a* were removed from tissue culture
dishes using a PBS EDTA mixture. Cells were resuspended at a con-
centration of 6 3 106/ml in an ice-cold PBS 20% FBS solution.
I125 NGF (Amersham) was diluted in a 20% FBS/PBS solution in clear
96-well v-bottom dishes (Corning) on ice. UnlabeledNGFwas included
where appropriate at >10003 concentration of the unlabeled NGF.
Cells were added to the NGF solution and incubated on ice for 90
min in a total volume of 60 ml, which included 60,000 cells. 200 ml of
ice-cold FBS was added, and the cells were spun in a refrigerated
tabletop Beckmanmicrofuge for 5min. @ 4,000 RPM. The supernatant
was removed with a multichannel pipetter and ultimately placed into
5ml of scintillation fluid for analysis of the ‘‘free’’ fraction. The cell pellet
was solubilized with scintillation fluid and placed into 5 ml of scintilla-
tion fluid for analysis of the ‘‘bound’’ fraction. Scintillation vials were
read on a beckman scintillation counter. The values from the back-
ground binding (wells that included 10003 unlabeled NGF) were sub-
tracted from the bound fraction values prior to Scatchard transforma-
tion. Background values averaged 21% ± 12% of the bound values.
Scatchard analysis of Trka* alone, p75a-FL*, and PC12 cells was
carried out in identical fashion. PC12 cells were grown in 10% horse
serum and 5% FBS on collagen-coated dishes.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/53/1/25/DC1/.
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